Jinan Hongyuan Chemical Co.,Ltd
86-13954187575
On October 8, Yifan Pharmaceutical issued an announcement that the long-acting G-CSF needle F-627 (Aibeguestine α) of Yiyi Biotech was issued by the European Medic
Yaozhi data shows that the new drug listing application of Siglita Sodium, a new class 1 drug for the treatment of diabetes by Microchip Biote
On October 9, Shanghai Pharmaceuticals issued an announcement that its wholly-owned subsidiaries, Shanghai Shangyao Xinyi Pharmaceutical Co.,
Recently, Jiangsu Hausen Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Hausen Pharmaceutical" or the "Company") i
Recently, Kelun Pharmaceutical announced the Phase I clinical data of SKB264 at the CSCO annual meeting. As of April 28, 2021, 17 patients hav
Along with economic development and the intensification of aging, people's health awareness is increasing, and the demand for p
On September 28, Hisun Pharmaceuticals announced that Hisun Bio, a wholly-owned subsidiary of Borui Bio, received the "Drug Reg
After the trough caused by the storm of drug registration and verification in 2006, the declaration of domestic innovative drugs began to grow slowly from 2009; After the implementation of the n
Currently, non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, and naproxen play an important role in the clinical trea
On September 22, Hainan Puli Pharmaceutical Co., Ltd. announced that it had recently signed a framework cooperation agreement o
According to the data of Yaozhi, Hengrui Medicine's application for the new indications of pyrrotinib maleate tablets was accep
On September 16, Luye Pharmaceutical Group announced that its subsidiary, Luye Pharmaceuticals (Switzerland), has reached an agreement with Esteve Pharmaceuticals,
Recently, Cinda Biotech and Jinfang Pharmaceutical reached a licensing agreement to obtain the latter's exclusive global development and commercialization rights fo
According to the data of Yaozhi, Hengrui Medicine's application for the new indications of pyrrotinib maleate tablets was
On September 15, 2021, Corning Jereh and Simcere announced that the clinical trial application of Envolimab Injection (R&D code: KN035) co
Just now, Shanghai Sunshine Pharmaceutical Purchasing Network issued the notice of "The sixth batch of nationally organized drug central
It is reported that at the upcoming ESMO this year, the head-to-head DESTINY-Breast03 research results of DS-8201 and T-DM1 wil
On September 8, 2021, Huadong Medicine (SZ.000963) and Insilico Medicine announced today that they have established a partnersh
Recently, the General Office of the National Health Commission issued a notice on the "Regulations for the National Key Monitor
On September 6, Hengrui Medicine issued an announcement stating that its subsidiary Shengdia Biomedicine had recently received
According to the latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, Haihe Pharmaceuticals/Shanghai I
On September 2, Hengrui Medicine announced that it had received the "Drug Supplementary Applicati
According to the consistency evaluation analysis system of Yaozhi Data Enterprise Edition, 68 new acceptance numbers for consis
On July 2, CDE issued the "Clinical Value-Oriented Anti-tumor Drug Clinical Research and Development Guidelines", which triggered a successive plunge in CRO concept
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
